| Literature DB >> 32215179 |
Habib Yaribeygi1, Thozhukat Sathyapalan2, Stephen L Atkin3, Amirhossein Sahebkar4,5,6.
Abstract
Type 2 diabetes mellitus (T2DM) is the most prevalent metabolic disorder characterized by chronic hyperglycemia and an inadequate response to circulatory insulin by peripheral tissues resulting in insulin resistance. Insulin resistance has a complex pathophysiology, and it is contributed to by multiple factors including oxidative stress. Oxidative stress refers to an imbalance between free radical production and the antioxidant system leading to a reduction of peripheral insulin sensitivity and contributing to the development of T2DM via several molecular mechanisms. In this review, we present the molecular mechanisms by which the oxidative milieu contributes to the pathophysiology of insulin resistance and diabetes mellitus.Entities:
Year: 2020 PMID: 32215179 PMCID: PMC7085395 DOI: 10.1155/2020/8609213
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Possible molecular mechanisms between oxidative stress and beta-cell dysfunction leading to diabetes mellitus. Pdx-1: insulin promoter factor 1; MafA: a transcription factor; TLRs: toll-like receptors; Nf-κb: nuclear factor kappa b; p38 MAPK: p38 mitogen-activated protein kinases; JNK/SAPK: stress-activated protein kinase/c-Jun NH(2)-terminal kinase.
Figure 2Oxidative stress impairs insulin signaling pathways by several molecular pathways. IST: insulin signal transduction; IRS-1: insulin receptor substrate-1; IKK-β: inhibitor of nuclear factor kappa B; GSK-3: glycogen synthase kinase 3; AMPK: AMP-activated protein kinase; mTOR: mammalian target of rapamycin; p38 MAPK: p38 mitogen-activated protein kinases.
Clinical trials undertaken with anti-inflammatory agents.
| Study population | Study design | Treatment | Dose | Results | Ref. |
|---|---|---|---|---|---|
| 81 patients with T2DM | Randomized double-blind placebo-controlled trial | Salsalate | 3.0, 3.5, or 4.0 g/d for 14 weeks | Reduced the HbA1c and FBG | [ |
| 20 obese nondiabetic adults | Randomized double-blind placebo-controlled trial | Salsalate | 4.0 g/day for 4 weeks | Declined FBG, HbA1c, and C-peptide and increased adiponectin | [ |
| 70 patients with T2DM | Randomized double-blind placebo-controlled trial | Anakinra, a recombinant human IL-1R | 13 weeks | Alleviated inflammatory markers and improved glucose control even after treatment withdrawal | [ |
| 15 patients with T2DM | Open-label triala and randomized double-blind placebo-controlled trialb | Salsalate | 3 and 4.5 g/d for 2 weeks | Improved glucose control, circulating free fatty acid, and adiponectin levels | [ |
| 286 patients with T2DM | Randomized double-blind placebo-controlled trial | Salsalate | 3.5 g/d for 48 weeks | Reduced mean HbA1c | [ |
| 257 patients with T2DM | Randomized double-blind placebo-controlled trial | Salsalate | 3.5 g/d for 30 months | Reduced inflammatory markers and FBG | [ |
| 7,000 patients with MI and insulin resistance | Randomized double-blind placebo-controlled trial | Methotrexate | 15-20 mg/wk for 3-5 years | Reduced inflammatory markers and HbA1c | [ |
Anakinra: a recombinant human IL-1 receptor; FBG: fasting blood glucose; HbA1c: glycated hemoglobin; MI: myocardial infarction. aTwo studies with open-label design at doses of 3 and 4.5 g/day. bOne study with a randomized double-blind placebo-controlled design.
Figure 3Oxidative stress induces insulin resistance via five major molecular pathways.
Main molecular mechanisms by which oxidative stress induces insulin resistance.
| Molecular mechanisms | Effects | Ref. |
|---|---|---|
|
| Induces beta-cell dysfunction through various molecular pathways such as apoptotic events, impairing KATP channels, inhibiting transcription factors as Pdx-1 and MafA, suppressing | [ |
|
| ||
| GLUT-4 expression and/or localization | Suppresses transcriptional factors involved in GLUT-4 expression as PPAR- | [ |
|
| ||
| Insulin signaling pathways | Negatively modulates normal IST via IRS-1 and IRS-2, IKK- | [ |
|
| ||
| Inflammatory events | Increase inflammatory responses which in turn induces insulin resistance in several pathways | [ |
|
| ||
| Mitochondrial dysfunction | Impairs normal function of mitochondria thereby reduces cellular capacity for glucose uptake by GLUT-4 transporters | [ |
PPAR-γ: peroxisome proliferator-activated receptor gamma; IST: insulin signaling transduction; CEB/Ps: CCAAT enhancer-binding proteins; HIF-1α: hypoxia-inducible factors alpha; MEF2: myocyte enhancer factor 2; IRS-1: insulin receptor substrate-1; Akt: protein kinase B; IKK-β: inhibitor of nuclear factor kappa B; GSK-3: glycogen synthase kinase 3; AMPK: AMP-activated protein kinase; mTOR: mammalian target of rapamycin; p38 MAPK: p38 mitogen-activated protein kinases.